Gene content    
CHEK2 ( by HUGO)
Checkpoint Kinase
Tumor suppressor gene
Checkpoint Kinase 2
RAD53
CDS1
CHK2
Cds1 Homolog
CHK2 Checkpoint Homolog
hCds1
LFS2
CHK2 (Checkpoint
S.Pombe) Homolog
CHK2 Checkpoint Homolog (S. Pombe)
HuCds1
PP1425
Checkpoint-Like Protein CHK2
Serine/Threonine-Protein Kinase Chk2
EC 2.7.11.1
Hucds1
EC 2.7.11
NCBI: 22q12.1    Ensembl: 22q12.1
CHK2_HUMANSize: 543 amino acidsMass: 60915 Da

  • Subunit: Homodimer. Homodimerization is part of the activation process but the dimer may dissociate following activation. Interacts with PML. Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1; modulates CHEK2 phosphorylation at Thr-68 in response to ionizing radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates its degradation in response to ionizing radiation. Interacts with CUL1; mediates CHEK2 ubiquitination and regulation Selected PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for CHEK2 (see all 38): 1GXC (3D) [IMAGE] 2CN5 (3D) [IMAGE] 2CN8 (3D) [IMAGE] 2W0J (3D) [IMAGE] 2W7X (3D) [IMAGE] 2WTC (3D) [IMAGE]
  • Tissue specificity: High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues [IMAGE] Pathway & Disease-focused RT2 Profiler PCR Arrays including CHEK2 (see all 8): DNA Damage Signaling Pathway in human mouse
  • Function:
    Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells
                          
    Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells
  • Catalytic activity:
    ATP + a protein = ADP + a phosphoprotein
  • Similarity:
    Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily
                          
    Contains 1 FHA domain
                          
    Contains 1 protein kinase domain [IMAGE]
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR000253FHA_domForkhead-associatedDomain
    IPR000719Prot_kinase_domProtein kinaseDomain
    IPR002290Ser/Thr_dual-sp_kinase_domSerine/threonine protein kinaseDomain
    IPR008271Ser/Thr_kinase_ASSerine/threonine protein kinase, active siteActive Sites
    IPR008984SMAD_FHA_domainSMAD/FHADomain
    IPR011009Kinase-like_domProtein kinase-likeDomain
    BlocksIPB000253Forkhead-associated (FHA)Forkhead-associated (FHA)

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process cellular protein catabolic process IMP GOA 11298456
    cellular response to DNA damage stimulus IMP GOA 16481012
    cellular response to DNA damage stimulus TAS GOA 9836640
    DNA damage checkpoint TAS GOA 10617473
    DNA damage induced protein phosphorylation IMP GOA 11298456
    double-strand break repair IMP GOA 18317453
    G2/M transition of mitotic cell cycle IMP GOA 16481012
    intrinsic apoptotic signaling pathway in response to DNA damage IDA GOA 12402044
    intrinsic apoptotic signaling pathway in response to DNA damage IMP GOA 12717439
    positive regulation of transcription, DNA-templated IDA GOA 17101782
    protein autophosphorylation IDA GOA 16794575
    protein phosphorylation IDA GOA 12717439
    protein stabilization IDA GOA 12717439
    regulation of protein catabolic process IMP GOA 17101782
    regulation of transcription, DNA-templated IDA GOA 12717439
    signal transduction in response to DNA damage IDA GOA 14744935
    Cellular Component colocalizes_with chromosome, telomeric region IDA GOA 15149599
    PML body IDA GOA 12402044
    Molecular Function identical protein binding IPI GOA 16794575
    protein binding IPI GOA 11298456
    protein homodimerization activity IDA GOA 16794575
    protein kinase binding IPI GOA 16481012
    protein serine/threonine kinase activity TAS GOA 9836640
    protein serine/threonine kinase activity IDA GOA 12717439

    Disorder & Mutation    
    Source Disease
    SWISS-PROTLi-Fraumeni syndrome 2 (LFS2) [MIM:609265]: A highly penetrant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTProstate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry
    SWISS-PROTOsteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating in bone-forming cells, affecting the ends of long bones. Note=The gene represented in this entry may be involved in disease pathogenesis

    CHEK2 cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene